Mitomycin C (Teva) Inj 20 mg vial: Hospital supply issue

Last Updated: 11 July 2024

Supply issue Hospital only Active

There is a supply issue affecting Teva mitomycin C (pharmacode: 2601761).

11 July 2024 Update

Resupply has been updated to September 2024. There is enough stock of the alternative, Omegapharm, to last until Teva Mitomycin C is available again.

Affected product

Mitomycin C

PCT only- Specialist

Presentation: Inj 20 mg vial
Brand: Teva
Pharmacode: 2601761
Subsidy: $1250.00
Measure / Qty: per 1

Alternative listed

Teva has sourced a supply of Omegapharma mitomycin C, which will be supplied under Section 29 until the Teva brand is back in stock. Teva has supplied the Omegapharma brand before, but registration has now lapsed.

This stock will have Australian packaging.

Presentation: Inj 20 mg vial
Brand: Omegapharm
Unapproved medicine supplied under Section 29.
Pharmacode: 2580160
Subsidy: $1250.00
Measure / Qty: per 1

Information about Omegapharm mitomycin C on the Australian Medicinewise website(external link)

Expected resupply September 2024

Teva (the supplier) expect Teva brand mitomycin C to be resupplied in September 2024.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.